(2,3,4,5,6-pentasulfooxycyclohexyl) hydrogen sulfate | 23330-83-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫酸及其衍生物
• 英文名称: (2,3,4,5,6-pentasulfooxycyclohexyl) hydrogen sulfate
• 英文别名: Inositol hexasulfate；myo-inositol hexasulfate；hexa-O-sulfo-myo-inositol；Hexa-O-sulfo-myo-inosit；myo-Inositol-hexasulfonsaeure；Inosit-hexasulfat
• CAS: 23330-83-8
• 化学式: C₆H₁₂O₂₄S₆
• 分子量: 660.543
• InChiKey: NBTMNFYXJYCQHQ-GPIVLXJGSA-N

物化性质

• 密度：
  2.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4.87
• 重原子数：
  36.0
• 可旋转键数：
  12.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  381.6
• 氢给体数：
  6.0
• 氢受体数：
  18.0

安全信息

• 海关编码：
  2906199090

反应信息

• 作为产物：
  描述：

  Inositol 在 吡啶 、 氯磺酸 、 氯仿 作用下， 生成 (2,3,4,5,6-pentasulfooxycyclohexyl) hydrogen sulfate
  参考文献：
  名称：

  Takahashi; Egami, Nippon Kagaku Zasshi, 1959, vol. 80, p. 1364

  摘要：

  DOI：

文献信息

• PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES
  申请人：Italfarmaco, S.A.

  公开号：EP1602644A1

  公开（公告）日：2005-12-07

  A naphthalenesulfonic acid or quinolinesulfonic acid of formula (I), wherein A is N or a CR8 formula group, where R8 is H, OH, NR10R11, independently from one another, where R10 and R11 represent H or C1-C6 alkyl or a group of formula NH-CO-R12, where R12 is C1-C6 alkyl or C6-C10 aryl; R1 and R2 represent H or SO3R9, independently from one another, where R9 is H, ammonium or a cation of an alkali or alkaline-earth metal; R3 is H or OH; and R4, R5, R6 and R7 represent H, an NR10R11 or NH-CO-R12 group, independently from one another; on the condition that (i) at least one of R1 or R2 is SO3R9, and (ii) at least one of R4, R5, R6 or R7 is an NR10R11 or NH-CO-R12 group, or their pharmaceutically acceptable salts; and a pharmaceutically acceptable excipient.

  一种具有化学式（I）的萘磺酸或喹啉磺酸，其中A为N或CR8配方基团，其中R8为H、OH、NR10R11，独立地，其中R10和R11分别代表H或C1-C6烷基或配方NH-CO-R12的基团，其中R12为C1-C6烷基或C6-C10芳基；R1和R2独立地代表H或SO3R9，其中R9为H、铵或碱金属或碱土金属的阳离子；R3为H或OH；R4、R5、R6和R7独立地代表H、NR10R11或NH-CO-R12基团；条件是（i）R1或R2中至少有一个为SO3R9，（ii）R4、R5、R6或R7中至少有一个为NR10R11或NH-CO-R12基团，或它们的药用可接受盐；以及药用可接受的赋形剂。
• [EN] 4,6-DI-(O-THIOPHOSPHATE)-INOSITOL-1,2,3,5-TETRA-O-SULFATE FOR C. DIFFICILE INFECTION<br/>[FR] 4,6-DI-(O-THIOPHOSPHATE)-INOSITOL-1,2,3,5-TÉTRA-O-SULFATE POUR UNE INFECTION À C DIFFICILE
  申请人：ETH ZÜRICH

  公开号：WO2017098033A1

  公开（公告）日：2017-06-15

  The present invention relates to inositol bisthiophosphates-tetrakissulfates, particularly for use in treating symptoms associated with Clostridium difficile infection.

  本发明涉及肌醇双硫代磷酸四硫酸酯，特别用于治疗与梭状芽孢杆菌感染相关的症状。
• OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF
  申请人：Akagera Medicines, Inc.

  公开号：US20210403463A1

  公开（公告）日：2021-12-30

  Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

  揭示了用于治疗结核病以及其他分枝杆菌和革兰氏阳性细菌感染的组合物和方法。这些组合物含有一种高效、选择性的奥沙林酮，高效地封装以最大限度地发挥低毒性药物的剂量潜力，并在血浆存在的情况下保持稳定。这些组合物在静脉注射后在循环中长时间循环，并保留其封装的药物，以便在细菌或分枝杆菌感染部位有效积累。与通常用于治疗这些感染的其他药物的每日或每日两次给药相比，结合长时间循环特性和高度稳定的药物滞留，可以实现高剂量，从而降低给药频率。
• Urea phosphite
  申请人：Dean William Frank

  公开号：US20060063675A1

  公开（公告）日：2006-03-23

  Urea Phosphite is a new composition of matter useful as a fertilizer and as a fungicide. It is made by reacting phosphorous acid with urea. Urea Phosphite is characterized by being a liquid produced in an unprocessed reaction, and by having phosphite as a phosphorus source and urea as a nitrogen source. The reaction products may be separated, blended with an admix and spray dried, or, dissolved in water.

  尿素亚磷酸盐是一种新的物质组成，可作为肥料和杀菌剂使用。它是通过将磷酸与尿素反应而制成的。尿素亚磷酸盐的特点是它是一种未经加工反应产生的液体，磷酸盐作为磷源，尿素作为氮源。反应产物可以分离，与混合剂混合并喷雾干燥，或溶于水中。
• POLYCANNABINOIDS, COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：University of Connecticut

  公开号：US20210322365A1

  公开（公告）日：2021-10-21

  Polymers comprising a plurality of cannabinoids, methods of preparation thereof, and methods of use to treat a number of disease conditions are reported. Also provided are polymer coatings, films, fibers, and non-woven fabrics for a variety of topical applications including stents, bandages, sutures, and transdermal patches.

  本文报告了包含多种大麻素的聚合物，其制备方法以及用于治疗多种疾病状况的方法。同时，还提供了用于各种局部应用的聚合物涂层、膜、纤维和无纺布，包括支架、绷带、缝合线和经皮贴片。